Myconostica launches "improved" Pneumocystis test in the EU and Canada
This article was originally published in Clinica
Myconostica has launched a new version of its MycAssay Pneumocystis test in Europe and Canada. The test detects the fungus Pneumocystis jirovecii, a major cause of pneumonia in immunocompromised people, including HIV/AIDS patients. It can provide results in three hours when combined with the firm's MycXtra fungal DNA extraction system, to help select appropriate drugs and improve patient outcomes. Manchester, UK-based Myconostica originally launched the real-time PCR test outside the US in April 2009. It says that the new version has "improved clinical performance and increased analytical sensitivity". Meanwhile, the company has signed a deal with Bactus (Huddinge, Sweden), making the latter the exclusive distributor of Myconostica's products in Sweden and Finland.